TY - JOUR
T1 - 2021 PACES expert consensus statement on the indications and management of cardiovascular implantable electronic devices in pediatric patients
T2 - Executive summary
AU - Writing Committee Members
AU - Document Reviewers
AU - Silka, Michael J.
AU - Shah, Maully J.
AU - Avari Silva, Jennifer N.
AU - Balaji, Seshadri
AU - Beach, Cheyenne M.
AU - Benjamin, Monica N.
AU - Berul, Charles I.
AU - Cannon, Bryan
AU - Cecchin, Frank
AU - Cohen, Mitchell I.
AU - Dalal, Aarti S.
AU - Dechert, Brynn E.
AU - Foster, Anne
AU - Gebauer, Roman
AU - Gonzalez Corcia, M. Cecilia
AU - Kannankeril, Prince J.
AU - Karpawich, Peter P.
AU - Kim, Jeffery J.
AU - Krishna, Mani Ram
AU - Kubuš, Peter
AU - LaPage, Martin J.
AU - Mah, Douglas Y.
AU - Malloy-Walton, Lindsey
AU - Miyazaki, Aya
AU - Motonaga, Kara S.
AU - Niu, Mary C.
AU - Olen, Melissa
AU - Paul, Thomas
AU - Rosenthal, Eric
AU - Saarel, Elizabeth V.
AU - Silvetti, Massimo Stefano
AU - Stephenson, Elizabeth A.
AU - Tan, Reina B.
AU - Triedman, John
AU - Von Bergen, Nicholas H.
AU - Wackel, Philip L.
AU - Chang, Philip M.
AU - Drago, Fabrizio
AU - Dubin, Anne M.
AU - Etheridge, Susan P.
AU - Kongpatanayothin, Apichai
AU - Moltedo, Jose Manuel
AU - Nabar, Ashish A.
AU - Van Hare, George F.
N1 - Publisher Copyright:
© 2021 The Authors
PY - 2021/11/1
Y1 - 2021/11/1
N2 - Guidelines for the implantation of cardiac implantable electronic devices (CIEDs) have evolved since publication of the initial ACC/AHA pacemaker guidelines in 1984 [1]. CIEDs have evolved to include novel forms of cardiac pacing, the development of implantable cardioverter defibrillators (ICDs) and the introduction of devices for long term monitoring of heart rhythm and other physiologic parameters. In view of the increasing complexity of both devices and patients, practice guidelines, by necessity, have become increasingly specific. In 2018, the ACC/AHA/HRS published Guidelines on the Evaluation and Management of Patients with Bradycardia and Cardiac Conduction Delay [2], which were specific recommendations for patients >18 years of age. This age-specific threshold was established in view of the differing indications for CIEDs in young patients as well as size-specific technology factors. Therefore, the following document was developed to update and further delineate indications for the use and management of CIEDs in pediatric patients, defined as ≤21 years of age, with recognition that there is often overlap in the care of patents between 18 and 21 years of age. This document is an abbreviated expert consensus statement (ECS) intended to focus primarily on the indications for CIEDs in the setting of specific disease/diagnostic categories. This document will also provide guidance regarding the management of lead systems and follow-up evaluation for pediatric patients with CIEDs. The recommendations are presented in an abbreviated modular format, with each section including the complete table of recommendations along with a brief synopsis of supportive text and select references to provide some context for the recommendations. This document is not intended to provide an exhaustive discussion of the basis for each of the recommendations, which are further addressed in the comprehensive PACES-CIED document [3], with further data easily accessible in electronic searches or textbooks.
AB - Guidelines for the implantation of cardiac implantable electronic devices (CIEDs) have evolved since publication of the initial ACC/AHA pacemaker guidelines in 1984 [1]. CIEDs have evolved to include novel forms of cardiac pacing, the development of implantable cardioverter defibrillators (ICDs) and the introduction of devices for long term monitoring of heart rhythm and other physiologic parameters. In view of the increasing complexity of both devices and patients, practice guidelines, by necessity, have become increasingly specific. In 2018, the ACC/AHA/HRS published Guidelines on the Evaluation and Management of Patients with Bradycardia and Cardiac Conduction Delay [2], which were specific recommendations for patients >18 years of age. This age-specific threshold was established in view of the differing indications for CIEDs in young patients as well as size-specific technology factors. Therefore, the following document was developed to update and further delineate indications for the use and management of CIEDs in pediatric patients, defined as ≤21 years of age, with recognition that there is often overlap in the care of patents between 18 and 21 years of age. This document is an abbreviated expert consensus statement (ECS) intended to focus primarily on the indications for CIEDs in the setting of specific disease/diagnostic categories. This document will also provide guidance regarding the management of lead systems and follow-up evaluation for pediatric patients with CIEDs. The recommendations are presented in an abbreviated modular format, with each section including the complete table of recommendations along with a brief synopsis of supportive text and select references to provide some context for the recommendations. This document is not intended to provide an exhaustive discussion of the basis for each of the recommendations, which are further addressed in the comprehensive PACES-CIED document [3], with further data easily accessible in electronic searches or textbooks.
KW - Ambulatory ECG monitoring
KW - Antiarrhythmic drug therapy
KW - Antitachycardia pacing
KW - Arrhythmogenic cardiomyopathy
KW - Asystole
KW - Atrioventricular block
KW - Bradycardia
KW - Brugada syndrome
KW - Cardiac channelopathies
KW - Cardiac transplantation
KW - Cardiomyopathy
KW - Cardiovascular implantable electronic devices
KW - Catecholaminergic polymorphic ventricular tachycardia
KW - Children
KW - Congenital heart disease
KW - Coronary artery compression
KW - ECG
KW - Echocardiography
KW - Endocardial lead
KW - Epicardial lead
KW - Expert consensus statement
KW - Genetic arrhythmias
KW - Heart block
KW - Heart failure
KW - Hypertrophic cardiomyopathy
KW - Implantable cardioverter defibrillator
KW - Insertable cardiac monitor
KW - Lead extraction
KW - Lead removal
KW - Long QT syndrome
KW - Low- and middle-income countries
KW - MR imaging
KW - Neuromuscular disease
KW - PACES
KW - Pacemaker
KW - Pediatrics
KW - Postoperative
KW - Remote monitoring
KW - Shared decision-making
KW - Sick sinus syndrome
KW - Sports and physical activity
KW - Sudden cardiac arrest
KW - Sudden cardiac death
KW - Syncope
KW - Transvenous
KW - Ventricular fibrillation
KW - Ventricular tachycardia
UR - http://www.scopus.com/inward/record.url?scp=85118526756&partnerID=8YFLogxK
U2 - 10.1016/j.ipej.2021.07.006
DO - 10.1016/j.ipej.2021.07.006
M3 - Article
C2 - 34333142
AN - SCOPUS:85118526756
SN - 0972-6292
VL - 21
SP - 349
EP - 366
JO - Indian Pacing and Electrophysiology Journal
JF - Indian Pacing and Electrophysiology Journal
IS - 6
ER -